

PROGRAM

5 & 12 OCTOBER 2020

Hepatitis B Virus Serum Biomarkers
Virtual Workshops

DATES

Workshop 1

Monday, 5 October 2020, 12:00:00 (UTC)

Workshop 2

Monday, 12 October 2020, 12:00:00 (UTC)

Corresponding times:

Melbourne	23:00:00	AEDT	UTC+11 hours
Beijing	20:00:00	CST	UTC+8 hours
Johannesburg	14:00:00	SAST	UTC+2 hours
Paris	14:00:00	CEST	UTC+2 hours
New York	08:00:00	EDT	UTC-4 hours
San Francisco	05:00:00	PDT	UTC-7 hours

Zoom Webinar

Please register via the link below:

https://unimelb.zoom.us/webinar/register/WN_Fw9qvcRET4GgRY40DjVfZA

Background & Objectives

5 & 12 OCTOBER 2020

Hepatitis B Virus Serum Biomarkers
Virtual Workshops

Functional cure, the loss of HBV surface antigen is the major goal of many HBV cure strategies, using direct acting antivirals and anti-HBV immune-stimulating responses. On the other hand, complete cure involves the elimination or inactivation of the covalently closed circular DNA (cccDNA) reservoir. As new therapies are developed and tested, there is an urgent need for serum biomarkers that can:

- Accurately correlate with cccDNA expression in the liver
- Predict HBsAg loss
- Measure stimulation of host antiviral immune responses
- Screen HBV carriers in order to identify those at high risk of developing hepatocellular carcinoma

Although a number of alternative HBV serum biomarkers have been proposed, including HBV RNA and core related antigen, their clinical relevance, in all settings of chronic HBV infection, has yet to be resolved.

In this workshop, a range of experts will discuss the latest advances and identify knowledge gaps in our understanding of serum biomarkers. They will discuss challenges that need to be overcome to ensure the utility of various biomarkers in the clinic and for screening new antiviral therapies. Presentations will be complemented by two in-depth discussion panels that will debate these challenges and propose a way forward.

Workshop 1

5 OCTOBER 2020

140 min total – All Times in UTC



Session Co-Chairs:

Timothy M. Block & Veronica Miller

Pre-session Housekeeping Rules

Capucine Penicaud

- 12:00-12:05 Welcome and aims of the workshop
Anna Kramvis
- 12:05-12:25 Summary of the Viral Serum Biomarker Landscape + QAs
Barbara Testoni
- 12:25-12:45 Summary of Immunological Serum Biomarkers Landscape + QAs
Kyong-Mi Chang
- 12:45-13:00 What is serum HBV RNA? +QAs
Florian Van Bömmel
- 13:00-13:15 What is core related antigen? + QAs
Jianming Hu
- 13:15-13:35 Utility of serum biomarkers to follow natural history and treatment of chronic hepatitis B + QAs
Harry Janssen
- 13:35-14:20 Industry Panel Discussion
Panel Co-Chairs: Adam Gehring and Ulrike Protzer
What are the virological and immunological gaps that need to be addressed?
What biomarkers are most needed to meet HBV cure endpoints?
QAs from audience in writing on Zoom, selected by the panel Co-Chairs

Workshop 2

12 OCTOBER 2020

140 min total – All Times in UTC



Session Co-Chairs:

Christian Bréchet & Ourania M. Andrisani

Pre-session Housekeeping Rules

Capucine Penicaud

- 12:00-12:10 Welcome by Peter Revill & Fabien Zoulim
ICE-HBV Chairmanship Handover
- 12:10-12:25 Biomarkers of HBV cccDNA expression + QAs
Maura Dandri
- 12:25-12:40 Biomarkers of Occult HBV infection+ QAs
Teresa Pollicino
- 12:40-12:55 Biomarkers of liver cancer+QAs
Patrizia Farci
- 12:55-13:10 Point of Care Testing - an unmet and urgent need + QAs
Daryl Lau
- 13:10-13:30 Bench to Bed: Relevance of biomarkers used in in vitro and in vivo model systems to the clinic. + QAs
Dieter Glebe
- 13:30-14:20 Industry Panel Discussion:
Panel Co-Chairs: Fabien Zoulim and Mala Maini.
What are the most clinically relevant biomarkers?
QAs from audience in writing on Zoom app, selected by the Panel Co-Chairs
- 14:20-14:30 Concluding remarks and next steps.
Anna Kramvis